≡ Risteys
R10

Documentation Changelog GitHub Contact & Feedback

Malignant immunoproliferative diseases (controls excluding all cancers)

Endpoint Browser PheWeb

CD2_IMMUNOPROLIFERATIVE_EXALLC

No definition available.

Endpoint definition

↥
FinnGen phenotype data

individuals

diagram downward connector

Apply sex-specific rule None

diagram downward connector

Check conditions None

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Hospital Discharge: ICD-10 C88
Cause of death: ICD-10 C88

2 out of 7 registries used, show all original rules.

-

diagram downward connector

Check minimum number of events None

-

diagram downward connector

Include endpoints None

-

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

250

diagram downward connector
CD2_IMMUNOPROLIFERATIVE_EXALLC

Control definitions

Control exclude C3_CANCER

Extra metadata

Level in the ICD hierarchy 3
First used in FinnGen datafreeze DF4
Parent code in ICD-10 C81-C96
Name in latin Morbi immunoproliferativi maligni

No upset plot: script not run.

No upset table: script not run.

Similar endpoints

↥

List of similar endpoints to Malignant immunoproliferative diseases (controls excluding all cancers) based on the number of shared cases.

Venn diagram with an highlighted set fully inside another set Broader endpoints:

Venn diagram with a set fully inside an highlighted set Narrower endpoints:

Show all endpoint correlations

Summary Statistics

↥

Key figures

All Female Male
Number of individuals 250 104 146
Unadjusted prevalence (%) 0.06 0.05 0.08
Mean age at first event (years) 66.48 64.66 67.77

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 - - - -
15 years - - - -
5 years - - - -
1 year - - - -

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: CD2_IMMUNOPROLIFERATIVE_EXALLC – Malignant immunoproliferative diseases (controls excluding all cancers)
GWS hits: 1

Survival analyses between endpoints

↥

Plot

before Malignant immunoproliferative diseases (controls excluding all cancers)
after Malignant immunoproliferative diseases (controls excluding all cancers)

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Malignant immunoproliferative diseases (controls excluding all cancers)

↥

Endpoint not on priority list, no data to show.